Plague in Guinea Pigs and Its Prevention by Subunit Vaccines

Quenee, Lauriane E.; Ciletti, Nancy; Berube, Bryan J.; Krausz, Thomas; Elli, Derek; Hermanas, Timothy M.; Schneewind, Olaf

doi:10.1016/j.ajpath.2010.12.028

Cited by 18 publications

(18 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The protective efficacy of recombinant F1 and V subunits against Y. pestis has been reported by a number of laboratories and in a range of laboratory animal models including guinea pigs [48,61], rats [62] and non-human primates [50,63]. Vaccination with these sub-units has been shown to protect animal models against flea-vectored plague [64] as well as against experimental Y. pestis challenges, including pneumonic infections [45,62,63,65], unlike KWCVs.…”

Section: Prospects For Vaccinationmentioning

confidence: 99%

Plague: Infections of Companion Animals and Opportunities for Intervention

Oyston

Williamson

2011

Animals

View full text Add to dashboard Cite

Plague is a zoonotic disease, normally circulating in rodent populations, transmitted to humans most commonly through the bite of an infected flea vector. Secondary infection of the lungs results in generation of infectious aerosols, which pose a significant hazard to close contacts. In enzootic areas, plague infections have been reported in owners and veterinarians who come into contact with infected pets. Dogs are relatively resistant, but can import infected fleas into the home. Cats are acutely susceptible, and can present a direct hazard to health. Reducing roaming and hunting behaviours, combined with flea control measures go some way to reducing the risk to humans. Various vaccine formulations have been developed which may be suitable to protect companion animals from contracting plague, and thus preventing onward transmission to man. Since transmission has resulted in a number of fatal cases of plague, the vaccination of domestic animals such as cats would seem a low cost strategy for reducing the risk of infection by this serious disease in enzootic regions.

show abstract

Section: Prospects For Vaccinationmentioning

confidence: 99%

Plague: Infections of Companion Animals and Opportunities for Intervention

Oyston

Williamson

2011

Animals

View full text Add to dashboard Cite

show abstract

“…When used as a vaccine in mice, rats, guinea pigs and non-human primates, rV10 immunization offered significant protection against pneumonic plague challenge [24, 46–48]. Analysis of IgG responses to immunization revealed that, in contrast to wild-type LcrV, rV10 vaccine elicited almost exclusively antibodies that recognize conformational epitopes on the plague antigen [47, 48]. …”

Section: Introductionmentioning

confidence: 99%

Prevention of pneumonic plague in mice, rats, guinea pigs and non-human primates with clinical grade rV10, rV10-2 or F1-V vaccines

Quenee

Ciletti

Elli

et al. 2011

Vaccine

Self Cite

View full text Add to dashboard Cite

Yersinia pestis causes plague, a disease with high mortality in humans that can be transmitted by fleabite or aerosol. A US Food and Drug Administration (FDA)-licensed plague vaccine is currently not available. Vaccine developers have focused on two subunits of Y. pestis: LcrV, a protein at the tip of type III secretion needles, and F1, the fraction 1 pilus antigen. F1-V, a hybrid generated via translational fusion of both antigens, is being developed for licensure as a plague vaccine. The rV10 vaccine is a non-toxigenic variant of LcrV lacking residues 271–300. Here we developed Current Good Manufacturing Practice (cGMP) protocols for rV10. Comparison of clinical grade rV10 with F1-V did not reveal significant differences in plague protection in mice, guinea pigs or cynomolgus macaques. We also developed cGMP protocols for rV10-2, a variant of rV10 with an altered affinity tag. Immunization with rV10-2 adsorbed to aluminum hydroxide elicited antibodies against LcrV and conferred pneumonic plague protection in mice, rats, guinea pigs, cynomolgus macaques and African Green monkeys. The data support further development of rV10-2 for FDA Investigational New Drug (IND) authorization review and clinical testing.

show abstract

“…We chose serum specimens in our study because blood is the most accessible and frequently assayed bodily fluid, and the most dangerous clinical presentations of plague are primarily from pneumonic and septicemic cases in which no buboes are present (Williams et al 1972). The detection limit when using silver enhancement was 10 2 -10 4 CFU/ml of Y. pestis, which was close to (or even better than) the sensitivity of mouse bioassay (10 3 CFU/ml, Quenee et al 2011). This enhanced strip assay is sufficiently sensitive to support effective in vitro Y. pestis distribution analysis and for use in field contamination detection, especially in cases of bioterrorist attacks that use plague as a biological weapon.…”

Section: Discussionmentioning

confidence: 98%

Rapid detection of Yersinia pestis recombinant fraction 1 capsular antigen

Tsui

Tsai²,

Chiao³

et al. 2015

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

Yersinia pestis, an infectious bacterium that is a causative agent of plague, a disease which has been shown to be one of the most feared in history and which has caused millions of deaths. The capsule-like fraction 1 (F1) antigen expressed by Y. pestis is a known specific marker for the identification of the bacteria; therefore, the detection of F1 is important for Y. pestis recognition. In this study, a rapid, sensitive, and specific technique, the lateral flow assay (LFA), was successfully developed to detect Y. pestis by the recombinant F1 antigen. The assay that utilized an anti-F1 polyclonal antibody (Pab) to identify the bacteria was based on a double-antibody sandwich format on a nitrocellulose membrane. With the LFA method, 50 ng/ml of recombinant F1 protein and 10(5) CFU/mL of Y. pestis could be detected in less than 10 min. This assay also showed no cross-reaction with other Yersinia spp. or with some selected capsule-producing Enterobacteriaceae strains. Furthermore, detection of Y. pestis in simulated samples has been evaluated. The detection sensitivity of Y. pestis in various matrices was 10(5) CFU/mL, which was identical to that in PBS buffer. The results obtained suggest that LFA is an excellent tool for detection of Y. pestis contamination in an environment and hence can be used to monitor plague diseases when they emerge.

show abstract

Plague in Guinea Pigs and Its Prevention by Subunit Vaccines

Cited by 18 publications

References 44 publications

Plague: Infections of Companion Animals and Opportunities for Intervention

Plague: Infections of Companion Animals and Opportunities for Intervention

Prevention of pneumonic plague in mice, rats, guinea pigs and non-human primates with clinical grade rV10, rV10-2 or F1-V vaccines

Rapid detection of Yersinia pestis recombinant fraction 1 capsular antigen

Contact Info

Product

Resources

About